RPG Life Sciences Ltd (RPGLIFE) — shareholding pattern, promoter holding, financials and share price
About RPG Life Sciences Ltd (RPGLIFE)
RPG Life Sciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as RPGLIFE and on the BSE under scrip code 532983. Its ISIN is INE105J01010.
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients [1]
RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets.
The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures.
Listed peers in Pharmaceuticals: Orchid Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, Zota Health Care Ltd, Unichem Laboratories Ltd, Gujarat Themis Biosyn Ltd, Gufic BioSciences Ltd.
Valuation & Returns
10 Jul 2026At ₹2,854.5 a share on 10 Jul 2026, RPG Life Sciences Ltd (RPGLIFE) was valued at a price-to-earnings ratio of 22.89x against an industry P/E of 36.41x and a price-to-book of 7.8x on a book value of ₹366.01 per share as of Mar 2026. Solomo computes return on equity of 34.07% and return on capital employed of 40.71% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 22.89x
- Industry P/E
- 36.41x
- P/B
- 7.8x
- EPS (TTM)
- ₹124.69
- Book value / share
- ₹366.01
- ROE
- 34.07%
- ROCE
- 40.71%
- ROA
- 26%
- Debt / equity
- 0.03x
- Dividend yield
- 0.84%
- EBITDA margin
- 24.96%
- 52-week range
- ₹1,731.25 – ₹2,889
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, RPG Life Sciences Ltd (RPGLIFE) reported revenue of ₹708 crore, net profit of ₹115 crore and earnings per share of ₹69.64. That compares with revenue of ₹653 crore and net profit of ₹183 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹177 crore and net profit ₹30 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 653 | 708 |
| Net profit (₹ cr) | 183 | 115 |
| EPS (₹) | 110.79 | 69.64 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.73% | 12.70% | 11.33% | 8.28% |
| Profit growth | 28.46% | 23.55% | 19.41% | -37.15% |
| Stock price CAGR | 27% | 45% | 44% | 10% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.95% of RPG Life Sciences Ltd (RPGLIFE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.95% and domestic institutional investors (DII) hold 8.67%. Market capitalisation was ₹4,721 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: Clarus Capital I 5.59%, Authum Investment And Infrastructure Limited 2.02%, Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.95% | - | 0.95% | 8.67% | 27.05% |
| Mar 2026 | 72.95% | - | 0.87% | 7.45% | 27.05% |
| Dec 2025 | 72.95% | - | 1% | 7.04% | 27.05% |
| Sep 2025 | 72.95% | - | 1.11% | 6.7% | 27.05% |
| Jun 2025 | 72.95% | - | 1.35% | 6.48% | 27.05% |
| Mar 2025 | 72.95% | - | 1.45% | 6.14% | 27.05% |
| Dec 2024 | 72.95% | - | 1.3% | 6.06% | 27.05% |
| Sep 2024 | 72.81% | - | 1.35% | 5.45% | 27.19% |